Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 17, 2015 (11 years ago)

Nifedipine Extended-Release Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications: High out of specification dissolution result at 1 hour time point.

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Nifedipine Extended-Release Tablets, USP, 90 mg, 100 Tablet Bottles, Rx Only. Manufactured for: Teva Pharmaceuticals USA Sailorsville, PA 13960. Manufactured in Canada By: Valeant Pharmaceuticals International, Inc. Steinbach, MB R5G 127 Canada. NDC: 0093-2059-01.

Affected NDC 0093-2059-01

Compare with the code on your package — it is the most precise check available.

Drug: Nifedipine Category: Blood Pressure Medication

Recalling firm
Valeant Pharmaceuticals North America LLC
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1116-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Nifedipine recalls

See all
Class II · Moderate risk

Nifedipine USP for prescription compounding

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-8025-2 D-0513-2018
Class III · Low risk

Adalat CC (nifedipine)

Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

Terminated Cross-contamination Alvogen, Inc D-0635-2017
Class III · Low risk

Adalat CC (nifedipine)

Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

Terminated Cross-contamination Alvogen, Inc D-0634-2017

Other recalls by Valeant Pharmaceuticals North America LLC

All 2015 recalls
Class III · Low risk

Diltiazem HCl CD capsules

Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

Terminated Dissolution failure Valeant Pharmaceuticals North America LLC NDC 68682-521-01 D-0491-2019
Class III · Low risk

Cardizem CD

Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

Terminated Dissolution failure Valeant Pharmaceuticals North America LLC NDC 0187-0798-30 D-0490-2019
Class III · Low risk

Cardizem CD

Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

Terminated Dissolution failure Valeant Pharmaceuticals North America LLC NDC 0187-0797-30 D-0489-2019
Class III · Low risk

Cardizem CD

Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

Terminated Dissolution failure Valeant Pharmaceuticals North America LLC NDC 0187-0796-30 D-0488-2019